Ser-Ap-Es

Hypertensive disease

Treatment

1 FDA approval

20 Active Studies for Ser-Ap-Es

What is Ser-Ap-Es

Reserpine

The Generic name of this drug

Treatment Summary

Hydrochlorothiazide is a medication used to treat swelling and high blood pressure. It is the most commonly prescribed thiazide diuretic, but its use is declining in favor of drugs such as angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. It was approved by the FDA in 1959 and is available in combination with other drugs.

Ser-Ap-Es

is the brand name

image of different drug pills on a surface

Ser-Ap-Es Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ser-Ap-Es

Reserpine

1960

8

Approved as Treatment by the FDA

Reserpine, also called Ser-Ap-Es, is approved by the FDA for 1 uses like Hypertensive disease .

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Polythiazide

Effectiveness

How Ser-Ap-Es Affects Patients

Hydrochlorothiazide helps the body get rid of more water through urine. The amount of hydrochlorothiazide taken will vary from person to person, but is usually between 25-100mg. People with weakened kidney or liver function should be especially careful when taking this drug.

How Ser-Ap-Es works in the body

Hydrochlorothiazide works by preventing the reabsorption of sodium and chloride, which causes water to be excreted from the body. This drug is transported from the blood into the cells lining the distal convoluted tubule in the kidneys, and then sent to the lumen of the tubule. Normally, sodium is reabsorbed into these cells and then pumped out into the bloodstream, causing a concentration gradient that encourages water to be reabsorbed. However, by blocking this reabsorption process, hydrochlorothiazide decreases the concentration gradient and reduces the amount of water that is reabsorbed by the body.

When to interrupt dosage

The suggested dosage of Ser-Ap-Es is contingent upon the identified condition, like Antepartum magnesium sulfate prevention, inadequately regulated blood pressure with single treatment and antihypertensives. The measure of dosage fluctuates in accordance with the technique of administration (e.g. Tablet, coated - Oral or Oral) recorded in the table beneath.

Condition

Dosage

Administration

Hypertensive disease

, 0.1 mg, 0.25 mg, 0.125 mg, 25.0 mg

Oral, Tablet, , Tablet - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

There are 20 known major drug interactions with Ser-Ap-Es.

Common Ser-Ap-Es Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Reserpine.

Amifostine

Major

Reserpine may increase the hypotensive activities of Amifostine.

Amisulpride

Major

Reserpine may increase the antipsychotic activities of Amisulpride.

Astemizole

Major

The metabolism of Astemizole can be increased when combined with Reserpine.

Axitinib

Major

The serum concentration of Axitinib can be increased when it is combined with Reserpine.

Ser-Ap-Es Toxicity & Overdose Risk

The lowest toxic dose of hydrochlorothiazide in mice and rats has been found to be greater than 10g/kg. Those who overdose on the drug may experience low levels of potassium, chloride, and sodium in the blood. To treat these symptoms, supportive care including fluids and electrolytes is recommended, as well as vasopressors to treat hypotension and oxygen for respiratory impairment.

image of a doctor in a lab doing drug, clinical research

Ser-Ap-Es Novel Uses: Which Conditions Have a Clinical Trial Featuring Ser-Ap-Es?

158 active clinical trials are currently examining the potential of Ser-Ap-Es in providing relief from Cirrhosis, Edema and Congestive Heart Failure.

Condition

Clinical Trials

Trial Phases

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Ser-Ap-Es Reviews: What are patients saying about Ser-Ap-Es?

5

Patient Review

1/29/2019

Ser-Ap-Es for High Blood Pressure

This drug has been the most effective in lowering my blood pressure to a normal level. I have tried many different drugs, but none of them have been as successful as this one.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ser-ap-es

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Ser-Ap-Es

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Ser-Ap-Es clinical trials?

We made a collection of clinical trials featuring Ser-Ap-Es, we think they might fit your search criteria.
Go to Trials
Image of Wayne Health Mobile Units in Detroit, United States.

Text Message Reminders for High Blood Pressure

18+
All Sexes
Detroit, MI

This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB# 100221MP2A), the purpose of which is to improve cardiometabolic health in two uniquely comparable cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center involves separate but related projects that aim to improve cardiometabolic health outcomes through better risk factor control for three chronic conditions that are of tremendous public health importance, (hypertension (HTN), heart failure, and coronary heart disease), all of which contribute significantly to premature death in Detroit and Cleveland. The present study is the prospective observational cohort component of ACHIEVE P1- EPI (Project 1) of the ACHIEVE GREATER Center and serves to characterize the population of patients with blood pressure (BP) levels above normal attending The Wayne Health Mobile Health Unit (MHU) events to better understand key factors (e.g., social determinants of health) that convey information about baseline BP levels and related clinical outcomes (e.g., follow-up clinic visits, BP control, and cardiovascular events).

Recruiting
Has No Placebo

Wayne Health Mobile Units

Steven J Korzeniewski, PhD

Have you considered Ser-Ap-Es clinical trials?

We made a collection of clinical trials featuring Ser-Ap-Es, we think they might fit your search criteria.
Go to Trials
Image of Northern Arizona University in Flagstaff, United States.

CardioCare Quest for High Blood Pressure

18+
All Sexes
Flagstaff, AZ

This project aims to address healthcare disparities among Navaho people diagnosed with hypertension or prehypertension through three main objectives. Firstly, it identifies and shares insights on healthcare access disparities affecting Navaho individuals experiencing nonadherence to hypertension treatment. Secondly, the proposal develops a telehealth solution based on factors identified as knowledge gaps caused by healthcare access disparities in hypertension management; we will use the factors to design a series of engaging minigames that can be incorporated into the larger CardioCare Quest. These minigames will be co-designed with end users and clinicians. Finally, the proposal conducts comprehensive qualitative and quantitative assessments of user experiences, perceptions, and challenges with CardioCare Quest.

Recruiting
Has No Placebo

Northern Arizona University (+1 Sites)

Tochukwu Ikwunne, PhD

Image of Tufts University in Boston, United States.

Food as Medicine for Cardiometabolic Health

18+
All Sexes
Boston, MA

Though the Mississippi Delta has a rich agricultural history and some of the nation's most fertile soil, residents have experienced the legacy of slavery and economic exploitation through food insecurity and poverty for generations. This project focuses on Bolivar, Washington, and Sunflower, contiguous counties in the Delta that are designated as health disparity populations. Over 65% of the 100,000 residents are Black/African American and \~30% live at or below the poverty level. Obesity rates are high and the rate of diabetes is almost double the national average. Tufts University received a grant from the National Institute of Minority Health and Health Disparities to develop, test, and evaluate a Food is Medicine program in Mississippi. The Delta Growing a Resilient, Enriching, Equitable, Nourishing food System (GREENS) Food is Medicine (FIM) Project, is a collaborative project in Bolivar, Washington, and Sunflower counties in Mississippi. The intervention involves regularly distributed fruit and vegetable produce boxes as well as nutrition education materials to the intervention group. The control group will receive produce boxes later, after they complete study activities. The project's primary goal is to improve health outcomes by creating a FIM intervention. The Delta GREENS FIM Project aims to become a model for promoting nutrition security and management of chronic conditions in varied communities nationwide.

Recruiting
Has No Placebo

Tufts University

Christina D Economos, PhD

Have you considered Ser-Ap-Es clinical trials?

We made a collection of clinical trials featuring Ser-Ap-Es, we think they might fit your search criteria.
Go to Trials